Symbols

ZYME

Zymeworks·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ZYME

Zymeworks Inc.

A company that develops multifunctional biotherapeutics for the treatment of cancer

Industry

Pharmaceutical

Established Date

Listing Date

12/16/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

264

Fiscal Year Ends

12-31

Website

www.zymeworks.com

Security Type

Common stock

Office address

108 Patriot Drive — Suite A, Middletown, Delaware 19709

Business

Introduction

Zymeworks Inc., was incorporated under the laws of the State of Delaware in June 2022. The company is a global biotechnology company that manages a portfolio of licensed medical assets and develops novel biotherapeutic product lines for cancer, inflammation and autoimmune diseases. Its strategy combines royalty aggregation, strategic acquisitions and internal innovation, and is underpinned by its proprietary multispecific antibody and antibody-drug conjugate technology platform.

Company Financials

EPS

ZYME has released its 2025 Q4 earnings. EPS was reported at -0.55, versus the expected -0.48, missing expectations. The chart below visualizes how ZYME has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ZYME has released its 2025 Q4 earnings report, with revenue of 2.52M, reflecting a YoY change of -91.90%, and net profit of -41.21M, showing a YoY change of -75.31%. The Sankey diagram below clearly presents ZYME's revenue sources and cost distribution.